Mitapivat, a novel experimental agent, represents a promising development in the treatment of red blood cell disorders such as pyruvate kinase deficiency (PKD). This unique drug functions as a potent PKR, boosting its activity and, consequently, improving erythropoiesis. Its mode of operation is believed to rectify metabolic abnormalities associate